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 The development and advancement of prostate cancer is supported by a plethora 
of genetic and proteomic abnormalities, including events of post-translational 
modifications. The protein arginine methyltransferase 5 (PRMT5) enzyme regulates 
epigenetic events of histone modifications and protein post-translational modifications 
within protein signaling pathways. PRMT5 functions by catalyzing the symmetric 
dimethylation of terminal arginine residues on target protein substrates. Under abnormal 
conditions of overexpression and upregulation, PRMT5 methyltransferase activity 
constitutively drives the growth and proliferation of dysregulated cells.  Overexpression 
or upregulation of PRMT5 correlates with disease progression as observed among 
numerous cancer types, including breast, colorectal, leukemia, lung, melanoma and 




growth and proliferation of lung and prostatic tumors, in vitro and in vivo. Plants 
naturally produce chemical toxins as mechanisms of defense against microbial and other 
biological threats. Human exploitation, consumption and application of agents isolated 
from plants for therapeutic intervention dates back throughout the millennia. In this 
study, we extracted, purified and evaluated natural, small, chemical compounds from 
plant products that antagonize PRMT5 activity in prostate cancer cells. We found that 
crude and purified extracts of Dendrobium aurantiacum var. denneanum (D. denneanum) 
plants attenuated prostate tumor growth and proliferation by selective inhibition of 
PRMT5 methyltransferase activity. These findings establish the first set of natural 
PRMT5-specific inhibitors reported. 
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 Metastatic Prostate adenocarcinoma is the leading cause of morbidity and the 
second-leading cause of cancer-associated mortality among American men.1, 3 The 
National Cancer Institute’s (NCI) Physician Data Query (PDQ) of cancer information 
states that the propensity for disease and deaths related to prostate cancer is influenced by 
both genetic and environmental factors.4 Of all males autopsied age 80 or older; nearly 
70% displayed some grade of incidental prostate cancer.5-6 Prostate cancer is an age-
related disease, however little is known regarding the specific biology underpinning the 
progression and recurrence of the disease.7 Data suggests that an accumulation of a 
variety of genomic and proteomic molecular events contributes to prostate tumor 
initiation and resiliency alike.8-9 According to the American Cancer Society (ACS), the 
five-year relative survival rate for American men diagnosed with localized or 
regionalized prostate cancer is 100%.10-11 However, American men diagnosed with 
distant metastases of prostate cancer have an anticipated five-year survival rate of less 
than 30%.10-11 In addition to other characteristics, unregulated cellular growth amid 
aberrant proliferation hallmarks the development and progression of malignant prostate 
cancer.12 A number of reports have implicated the family of protein arginine 




cancer.12-16 Protein arginine methyltransferases function by transferring methyl groups 
onto select arginine amino acid residues located on target substrates.17-19 Hyperactivity of 
PRMTs correlates with disease and is observable in multiple tissue types including 
bladder, blood, breast, colon, lung, ovarian and prostate cancers.20-25 Occurrence of 
nearly 80% of all mammalian asymmetric dimethylation activity is resultant of PRMT1.26 
Whereas the majority of type II symmetric dimethylation events are resultant of the 
mammalian PRMT5.27 Previously, we published that localization of PRMT5 to the 
cytoplasm of lung cancer cells was essential for growth of lung cancer cells.21 
Additionally, we found that overexpression of PRMT5 correlated with promotion of 
cellular growth and proliferation in prostate cancer cells.25  
1.1 Hypothesis  
Whether PRMT5 hyperactivity promotes tumor resiliency by regulation of histone 
tails to effect gene expression, modification of protein signaling to activate or inactive 
signaling pathways and coax crosstalk of signaling pathways or another mechanism, is 
unknown. The upregulation or overexpression of PRMT5 in cancer presents a relevant 
opportunity for targeted therapeutic intervention. Chemical inhibition of PRMT5 
potentiates opportunities to ameliorate its constitutive methyltransferase activity and 
mitigate the metastatic phenotype of prostate adenocarcinoma.  Considering the results of 
our previously published findings and the chemotherapeutic data of medicinal molecules 
derived from plants, we investigated the hypothesis that, natural compounds are 
sufficient to antagonize growth and proliferation of prostate adenocarcinoma by 




1.2 Purpose of the Study 
We methodically and objectively evaluated the hypothesis and its alternatives 
according to the following three specific aims:  
 
Aim 1: To extract and purify natural chemical compounds from Dendrobium 
aurantiacum var. denneanum. Natural chemical compounds obtained from plant, fruit 
and vegetable derivatives exhibited anti-tumorigenic effects against multiple cancer 
types.28-29 Our preliminary studies revealed successful extraction of a variety of natural 
crude products from another species of the orchid plant, Dendrobium nobile (D. nobile). 
We began optimizations for extraction of D. denneanum 
 
Aim 2: To test the purified chemical compounds for inhibition of PRMT5 activity.  
Previously, we reported that PRMT5 and its enzymatic activity are required for cellular 
growth of prostate and lung cancer cells.  Using an in vitro model, we evaluated crude 
and purified compounds for the ability to antagonize PRMT5 methyltransferase activity. 
We determined a minimum enzyme inhibitory concentration for the crude extract and 
each purified compound.   
 
Aim 3: To evaluate the effect of purified, natural compounds on growth and 
proliferation of cancer cells. Previously, we observed and reported PRMT5 localized to 
the cytoplasm of prostate cancer cell drives growth and proliferation. We evaluated the 




report the evaluation and characterization of the first known set of novel natural PRMT5-
specific inhibitors with micromolar efficacy. This research extracts, purifies and 
evaluates novel, natural PRMT5-inhibitory small chemical compounds for the prevention 
and mitigation of advanced prostate cancer.  
1.3 Statement of the Problem 
The aberrant hyperactivity of PRMT5 underpins the age-related morbidity 
and metastatic-associated mortality of prostate cancer. Failure to address and abate 
perturbations of PRMT5 activity may contribute to greater rates of metastatic 
prostate cancer and augment cancer-related mortality rates. Currently, there exists 
limited availability of clinically relevant PRMT5-specific inhibitors. After using a 
combination of biochemical techniques to extract, purify and evaluate chemical 
compounds, we report here for the first time, natural, powerful probes that exhibit 







2.1 Hallmarks of Cancer 
Highlighting a conserved set of distinct characteristics observed to be indicative 
of cancers are six acquired biologic properties proposed by Hanahan and Weinberg 
reported in Figure 1.12, 30 The organizing principle characterizes the initiation and 
development of neoplasia throughout the multistep succession to tumor pathogenesis. 
This comprehensive list of tumor qualities refers to phenotypic traits that enables 
unregulated growth and perpetuates proliferative states of cancers.  
 
Figure 1. The Hallmarks of Cancer.12 Six biological characteristics explain the acquired aberrant properties that cancer 





Angiogenesis is a process of generating new blood vasculature for the 
maintenance of the cellular microenvironment.31 Blood vasculature innervates tissues of 
organ systems with an overarching duality of purpose: to transport nutrients and remove 
waste. In men, the generation of most blood vasculature occurs during periods of normal 
growth and development.31 Typically, abnormal physiologic conditions or rare 
circumstances, like the destruction or damage to preexisting blood vasculature, warrants 
activation of angiogenesis.  More so than normal cells, cancer cells require nutrients in 
order to sustain the energetic demands associated with incessant development of 
dysregulated growth and divisions.10, 32  
The major mechanism by which cancer cells acquire access to additional nutrients 
is achieved by manipulating protein signaling networks to coax the establishment of new 
blood vessels from preexisting blood vasculature.33-34 Tissue maintenance relies upon the 
balance of a number of inhibitory and stimulatory factors of angiogenesis. Cancer cells 
hijack and upregulate the secretion of molecules like vascular endothelial growth factor 
(VEGF) to chemically attract and direct the generation of new blood vasculature.35 
Angiogenesis promotes the establishment and maintenance of the tumor 
microenvironment by directly innervating tumors with blood vasculature for nutrient 
delivery.31, 34-37 
2.1.2 Invasion and Metastasis  
Invasion and metastasis collectively refer to the migratory phenotypes exhibited 




Cellular movement employed by normal cells typically occurs over short distances for 
processes of cellular turnover, during which nascent cells replenish preexisting cells. 
Cellular motility is essential for the normal growth and development of tissues, wound 
healing and tissue maintenance. More specifically, normal cells anchor to adjacent cells 
in order to maintain tissue-specific morphology and function and protect tissue 
architecture. Cells harboring anomalies with regard to anchorage-dependence, enables 
properties of cellular motility that disregard tissue integrity while promoting remote 
trafficking.  
A compromise in tissue polarity due to abnormal tissue architecture with the loss 
of anchorage proteins like E-cadherin lays the foundation for both invasion and 
metastasis.38-39 The migration of cells from sites of primary tumors to distant organs of 
the body is an acquired trait that is indicative of an elite and resilient class of abnormal 
cells. The invasion and anchoring of tumorigenic cells into foreign tissues precipitates 
organ loss of function and subsequent organ failure. Consequentially, men who die of 
prostate cancer typically exhibit metastatic disease.  
The acquired ability to engineer context-specific morphological plasticity, 
traverse cellular borders of nearby tissues, withstand detection by immune surveillance, 
withstand changes in pressure and pH within the blood vasculature and operate in 
environments of temporary nutrient deprivation for the formation of metastatic sites 
describes aspects of tumor growth and survival.37, 40 Abandonment of tissue architecture 





2.1.3 Avoidance of Apoptosis 
The acquired ability of cells to escape elaborate programs that instruct 
dysfunctional cells to commit programmed cell death is apoptosis. Programmed cell 
death functions as a major antagonist to cancer development by discouraging the 
formation of tumors. Tumor-suppressor and auxiliary proteins surveil the cellular 
microenvironment for signs of distress beyond repair. Upon experiencing extenuating 
genomic insults, individual cells typically sacrifice themselves by suicide in a tightly 
regulated mechanism to protect overall tissue integrity.42  
Under the auspice of the BH3 family of proteins, diverse intercellular damage 
signals regulate the fate of cells by promoting cell survival or apoptosis.43-44 Another 
means for regulation of cellular turnover, aberrant cells expressing high levels of c-Myc 
is sufficient to commit cells to apoptosis.45 Cancer cells develop mechanisms that enable 
evasion of apoptosis in order to prolong survival.43-45 During less severe events of cellular 
stress in which damage to DNA is repairable, cells invoke autophagy as a means of 
cellular recovery.46-47 Autophagy enables molecule-specific degradation as a mechanism 
that attempts to rescue damaged calls. Although there exists considerable and context-
dependent overlap, apoptosis and autophagy function as opposite ends of a seesaw, 
regulating cellular fate.48 Under abnormal conditions, cells can rely more on autophagy as 
a mechanism for avoidance of apoptosis while contributing to the establishment and 






2.1.4 Replicative Immortality 
In order to develop macroscopic tumors, cancer cells must sustain a significant 
level of division cycles that support size maintenance or augmentation. Programs that 
restrict replication to a limited number of division cycles or signal for cells to die after 
irreparable damage, govern cellular replication cycles under normal conditions. Strand 
length of deoxyribose nucleic acid (DNA) shortens with each cycle of replication until 
reaching a point at which normal cells can no longer divide. These cells typically do not 
die; however, they also do not replicate. They are senescent. Excessive or overwhelming 
damage to DNA that is beyond salvation in normal cells leads to cellular death for 
purposes of protecting the integrity of overall tissue.  
The Hayflick limit refers to the maximum number of division cycles specific to 
that cell’s DNA strand length. Normal cell replication governs cellular division cycles by 
shortening the protective telomere cap on the end of DNA strands with each cycle of 
division.49-50 Telomeres shorten with each cycle of replication until reaching a critical 
point; beyond the critical number of divisions, cells enter into senescence and can no 
longer replicate.49-50 Dysfunctional cells achieve excessive rounds of division without 
consequences of cellular death or senescence. Tissue size augmentation potentiates 
disruption of tissue integrity.   
In opposition to canonical cellular signaling, cancer cells undergo an undefined 
number of replicative events whereas normal cells are restricted to a limited number of 
division cycles.50 In a transgenic murine model, telomeres independently promoted 




provides a novel implication that telomeres function to promote infinite division cycles 
independent of Hayflick’s limit. To combat restrictions imposed by Hayflick’s limit, 
cancer cells often upregulate activity of the enzyme telomerase in order to sustain an 
unspecified number of replicative events and promote the tumor microenvironment.52   
2.1.5 Constitutive Proliferative Signaling 
The prognostic evidence of proliferation is observable as augmentation in cell 
number resultant of a combination of growth and cellular divisions as illustrated in Figure 
2.53 Under normal circumstances, checkpoints of proliferation and nutrient homeostasis 
regulate biologic demands by toggling growth and development with respect to energetic 
demands for tissue turnover, scaffolding, size and morphology.32, 54 Chronic proliferation 
promotes dysfunction of tightly regulated checkpoints for the development and 
advancement of carcinogenesis.  
Loss of function in the SNAIL1 transcription factor generates a loss in cellular 
polarity and tissue architecture leading to the upregulation of oncogenes, downregulation 
of epithelial cadherin (E-cadherin) and promotion of an epithelial-to-mesenchymal 
transition (EMT) phenotype, enabling constitutive proliferative signaling.39, 55 Cancer 
stem cells (CSC) also contribute to proliferation by way of enabling accumulation of 
genetic mutations while exhibiting resistance to chemotherapy, resistance to apoptosis 
and properties of self-renewal.56 Dysregulation of one or a number of molecular events 
involving genetic mutations, EMT, or stemness potentiates conditions that promote 
sustained proliferative signaling for establishment and promotion of the tumor 





Figure 2. Loss of SNAIL promotes proliferation.57 
2.1.6 Unregulated Growth 
Tumor suppressor genes code for proteins that function to suppress the formation 
of tumors.58 Alternatively, oncogenes code for proteins that function to promote events 
that contribute to the formation of tumors.58 For purposes of sustaining signals that 




genes as reported in Table 1.59-61 Surveillance by an integrated network of internal and 
external signals regulates cellular entrance into Mitosis. 
 
Table 1. Cancer Hallmarks Establish the Tumor Microenvironment.57 
Factor Contribution to Carcinogenesis  
EMT Promotes stem cell growth, metastasis 
Hypoxia HIFs promote proliferation of CSCs and angiogenesis; alters metabolism 
Autophagy Promotes cell survival resultant of dysregulated signaling-mediated proliferation 
CSCs Dysregulation in “stemness”, quiescence, self-renewal, resistance to apoptosis 
Cell Cycle 
Proteins 








Promotes altered survival and growth in adverse conditions 
Hormone 
Signaling 
Promotes the growth of hormone responsive cancers through constitutive activation 
of estrogen and androgen signaling pathways 
Tumor 
Microenvironment 
Stromal cell crosstalk promotes growth and metastasis of cancer stem cells 
 
Intrinsic sensors or receptors mediate information received from transducers or 
signals that quickly respond to metabolic requirements for cellular growth. In order to 
maintain the delicate balance of tumor prevention, gene products that suppress tumors 
like p53 and RB, closely surveil DNA and intervene to arrest cell growth whenever 
genomic damage is beyond repair.58, 62-63Additionally, loss of function in the tumor 
suppressor Nf2 leads to restriction of EGFR in the cellular membrane attenuating contact-
dependent inhibition of adjacent cells.64 Similarly, loss of function of the tumor 
suppressor LKB1 promotes multiple Hallmarks of Cancer including unregulated growth.65 




formation of tumors, promoting unregulated cellular growth for establishment and 
promotion of the tumor microenvironment as reported in Table 1. 
2.1.7 The Tumor Microenvironment  
The Hallmarks of Cancer represent six biological characteristics essential to all 
cancer types.12, 30, 66 Each of the designated characteristics are not exclusively unique to 
cancer; rather the aberrant function of each characteristic beyond its canonical function is 
the basis for which cancer initiates and persists. One characteristic alone mentioned here 
is not sufficient to declare a tumor malignant. Rather, the authors stress that malignant 
tumor cells exhibit six phenotypes beyond the innate biological characteristics of normal 
cells that establish, maintain and promote aspects of the tumor microenvironment as 
depicted in Figure 3.  
 




To go on, cancer manifests as the culmination of a complex integration of canonical 
and awry signals and oncogenic events that vary across cell and organ type, as reported in 
Figure 3.66 A unique feature harbored within solid tumors are normal cells that maintain 
the ability to acquire oncogenic and tumorigenic hallmark traits while establishing and 
sustaining the tumor microenvironment. Given the consistency and prevalence of 
perturbations of each cancer characteristic, targeting each of the hallmarks for individual 
or concomitant inhibition potentiates promise for mitigating the onslaught of cancer disease 
incidence and progression. 
2.2 The Human Prostate and Prostate Cancer   
2.2.1 The Human Prostate 
Similar in shape and size to that of a walnut, the prostate is a gland of the male 
reproductive organ situated around the urethra, inferior to the bladder and anterior to the 







Figure 4. Anatomy and orientation of the male reproductive system.10 The prostate is located below the bladder and in 




The prostate assists with numerous physiological functions that promote optimal 
maintenance of male reproductive health.68 The smooth contractile muscles of the prostate 
influences management of urine flow rate as well as composition and secretion of seminal 
fluids.68 The prostate gland secretes anticlotting factors promoting the motility of semen to 
ensure a successful journey to the cervix.69 The prostate regulates the initiation for penile 
erections by controlling blood flow.  
The prostate is an androgen-regulated exocrine gland.70 Androgens facilitate 
normal growth, development and maintenance of canonical prostatic physiology.68, 71 
Under aberrant conditions, androgen receptor (AR) signaling functions in overdrive 
greatly enhancing the growth and division of prostatic cells.70 Sustained aberrant 
signaling of the AR can lead to inflammation and enlargement of the prostate gland, 
generating a condition of benign prostate hyperplasia (BPH).70-71 The prostate expresses 
the enzyme, 5 α-reductase, the major stimulator of the hormone that drives growth, 
development and maintenance of the prostate.68 Testosterone is the predominant 
circulating serum androgen in men. The enzyme 5 α-reductase converts testosterone into 
dihydrotestosterone (DHT). While the AR binds both testosterone and DHT, the affinity 
for DHT to AR is two-folds greater than that of testosterone.72 Additionally, testosterone 
dissociates from the AR five times faster than DHT.73 Prostate cancer is an age-related 
disease, driven initially by constitutive signaling of the androgen receptor.  
Factors like age, ethnicity, family history, accumulations of genetic abnormalities, 
caloric-rich and nutrient-deficient dietary practices, exposure to environmental 




homeostatic imbalance of the cellular microenvironment.74-78 Dysregulation of the 
cellular microenvironment at the level of the prostate potentiates the development of 
prostatitis, subsequent enlargement of the prostate and ultimately, cancer of the 
prostate.70-71, 74  
2.2.2 Prostate Cancer 
According the NCI’s Surveillance, Epidemiology and End Results (SEER) 
program, there is an estimated 164,960 new cases of prostate cancer expected, accounting 







The NCI estimates that 29,430 American men will die of prostate cancer-related 
deaths in 2018.1 Taken together, prostate cancer is currently the leading cause of 
morbidity and the second-leading cause of cancer-related mortality among American 
Figure 5. Incidence and mortality trends in prostate cancer.1 United States prostate cancer 
incidence and mortality trends from 1992-2015 as reported by SEER. Total number of 
new cases of prostate cancer reported each year. Total number of deaths attributed to 




men.1, 3 According to the American Cancer Society, the five-year survival rate for 
American men diagnosed with regional prostate cancer is 99%, reported in Figure 6. 
 
 
Figure 6. Prostate cancer survival. SEER data reporting the stage-adjusted 5-year relative survival rate for prostate 
cancer after initial diagnosis.1 Data reported reflects statistics acquired from patients that followed recommended 
clinical treatments immediately following diagnosis. 
 
However as reported in Figure 6, American men diagnosed with distant 
metastases of prostate cancer have an anticipated five-year survival rate of less than 
30%.1 
Prostate cancer disproportionately affects men of African descent than Caucasian 
counterparts.1, 3-4, 63 The average time of incidence of prostate cancer is 66 years of age in 




ancestry.1 Like most other cancers, prostate cancer is an age-related disease.62-63 Of all 
men autopsied at least 70 years of age or older, 35% of Caucasian-American men and 
50% of African-American men harbored undiagnosed tumors.6 While prostate cancer is 
chiefly a disease of accumulated genetic abnormalities, other variables such as 
environmental factors, lifestyle and diet serve as major possible influences to disease 
onset and progression.79 The aforementioned variables can also influence the patient’s 
prognosis in response to detection, treatment options and prognosis. 
The current widely practiced treatments for advanced prostate cancer including 
hormone therapy, chemotherapy, radiotherapy and immunotherapy does little to 
ameliorate the prognosis for patients with metastatic prostate cancer.10 There exists a 
need for novel therapeutic practices that balance sensitivity and specificity when 
targeting biological perturbations for the treatment of late-stage prostate cancer.  
2.2.3 Current Trends in Screening 
Screening for prostate cancer involves the patient, physician, other medical 
practitioners or a combination of the aforementioned. Screening for prostate cancer 
begins at home with self-examination observing for complications with the male urinary 
system. However, many cases of prostate cancer are indolent and do not manifest with 
symptoms detectable by observation through self-examination alone. Methods that are 
more specialized including the assistance received from trained healthcare professionals, 
provides the greatest documented opportunity for detecting prostate cancer early.6, 80 
Practices that screen for prostate cancer are specialized in their ability to detect yet 




parameters that surveil for the detection of abnormal physiology as compared against 
known standards of normal physiology. Some parameters for comparison employed 
during screenings include age, organ type, physiological function, and previous medical 
history. Dedicated screening practices for prostate cancer lack diagnostic or even 
detection efficacy.  
Although there currently exist controversy surrounding guidelines for 
recommended screening practices, there are two practices currently in-use. The accepted 
and widely practiced methods for the surveillance of prostate cancer include a 
recommended annual screening for all men older than 50 years of age utilizing the Digital 
Rectal Exam (DRE) and/or Prostate Specific Antigen (PSA) test.1, 10, 81-82 Current 
evaluations seek to determine if the recommendation of annual screening provides more 
benefit than harm.81, 83-85  
2.2.3.1 Digital Rectal Exam 
 DRE is a moderately invasive, same-day manual examination of the prostate. 
While standing and bending at the waist or lying on one’s side, a trained urologist inserts 
two lubricated, gloved fingers into the rectum of the patient. While sliding fingers across 
the prostate, the physician observes for lumps, areas of rigid tissue or enlargement of the 
prostate among other possible anomalies. The patient is sometimes encouraged to take 
and calmly expel a deep-breath of air during the examination in order to assist with the 
procedure. Generally, a patient does not experience physical complications following a 





2.2.3.2 Prostate Specific Antigen 
The PSA test is a minimally invasive screening of blood for detection of the 
protein, prostate specific antigen secreted from cells of the prostate. Typically, a 
pathologist or other healthcare provider uses a syringe to draw a sample of blood from 
the arm of a male patient. Analysis of the blood sample occurs in a dedicated laboratory 
for quantification of PSA in the blood, reported in ng/mL. Possible complications that a 
patient may experience following a PSA test include but is not limited to acute pain due 
to the stretching of skin or rupture of hemorrhoids or fissures, if present.  
In 1994, the United States Food & Drug Administration (USFDA) approved the 
use of the PSA test in conjunction with the DRE for surveillance and early detection of 
prostate cancer at clinic in asymptomatic men, with hopes of identifying cancer early 
enough to provide intervention and reduce morbidity and mortality.86 However, the 
United States Preventative Services Task Force (USPSTF) concluded from review of 
multiple screens of PSA clinical trials that a potential reduction in cancer death risk does 
not outweigh the benefits of screening and does not recommend the use of PSA as a 
prognostic marker for the detection and diagnosis of prostate cancer.87 Rather, the 
USPSTF recommends limiting PSA screenings to patients of African descent or those 
whom have a family history of the disease.87 Alternatively, the American Urological 
Association (AUA) maintains that screening for PSA after the diagnosis and treatment of 





Results of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial 
suggests minimum prognostic value for reliance on data obtained from using the DRE 
with regard to leveraging patient comfort and limitations due to a small sample size of 
patient participants of African descent while improving the accuracy and sensitivity for 
detecting early-stage prostate cancer.84, 88 After evaluation of data obtained from a 
comprehensive study involving six medical university centers, investigators found that 
the DRE provided slightly less of a statistical value as a prognostic marker when 
compared to PSA analyses alone.89 The combination of screenings using the DRE 
combined with results from PSA analyses only slightly improved the prognostic value 
from either exam alone.89  
Although there exists a large body of conflicting scientific data available to the 
public regarding the best screening practices recommended for American men, the single, 
least-invasive, strongest trends in literature suggests that using PSA as a prognostic 
marker for screening of prostate cancer is more predictive than other currently available 
methods.81, 83, 90-91 More research is required to determine the methods that balance 
efficacy and safety for screening for prostate cancer without limitations resultant of 
results bias, poor sensitivity or poor target specificity. Leading data trends suggests that 
the safest practices encourage each patient to make informed decisions guided by support 
from his medical team given the potential advantages, risks and limitations of each 
screening or detection method.1, 10, 90-93 A major challenge facing patients and physicians 
alike is the avoidance of over-screening and over-diagnosis and subsequent over-




2.2.4 Current Trends in Diagnosis 
Diagnosis of prostate cancer involves the patient, an urologist and a pathologist. 
Reliable detection of prostate cancer begins at clinic once the medical team acquires and 
analyzes a sample of the suspected tumor mass. The timing and type of test(s) used for 
the diagnosis of prostate cancer vary across medical practices and medical staff, alike. 
Additionally, the validity and sensitivity of each test possesses advantages and 
disadvantages, each specific to the patient’s status at presentation, timing and type of test 
administered, among other possible variables.  
Evaluations employed for the diagnosis of prostate cancer are specific in their 
ability to diagnose cancers of the prostate but no other cancers. More specifically, 
diagnostic mechanisms utilize a small number of biological markers or molecular probes 
that are unique to prostatic tissues and typically aberrantly expressed in cells of the 
cancer but not normal cells. For its extreme level of sensitivity, reverse-transcription 
polymerized chain reaction (RT-PCR) analysis presents as a reliable tool for the detection 
of messenger ribonucleic acids (mRNA) as an indicator of biomarker presence in tissues 
sampled. Some prostate cancer diagnostic tools include tissue biopsy, magnetic resonance 
imaging (MRI) scan, computerized tomography (CT) scan, and a bone scan with or 
without x-rays, an ultrasound or a urine flow test. Dedicated diagnostic tools for prostate 
cancer lack efficacy for the detection or diagnosis of cancers not of the prostate.  
2.2.4.1 Tissue Biopsy  
A prostate tissue biopsy is an invasive procedure for the removal of a sample of 




medical personnel guided by ultrasound, insert a specialized needle for biopsy through 
the rectum into the prostate to collect a small sample of cells from the aberrant mass as 
well as a separate collection of normal cells adjacent to the aberrant mass. A trained 
pathologist evaluates the biopsied cells underneath a microscope to determine if the 
obtained sample reveals cancerous cells. Cellular morphology and molecular marker-
specific colorimetric stains assist the pathologist in discerning cancer cells from non-
cancer cells. Possible and sometimes common side effects following a needle biopsy 
include but are not limited to bleeding, blood in the urine, and blood in semen, difficulty 
with urination or infection of the sampled area. 
2.2.4.2 Magnetic Resonance Imaging 
An MRI scan is a non-invasive medical procedure that applies a considerably 
strong magnetic field across the area encompassing the patient’s prostate forcing the 
alignment of hydrogen molecules.94 Simultaneously, radio waves pass through the scan 
area generating high-resolution, cross-sectional images of solid tissues within organ 
systems.95 Performed by a staff of trained medical professionals, this procedure positions 
the patient anatomically inside of the MRI machine that scans the prostatic region in 
360°. Upon conclusion of the scan, superimposed images generate a 3-dimensional (3D) 
composite of the gland and possible masses present. Alternatively, adjacently aligned 
images generate composites of the gland and possible masses for a topographical view. 
Sometimes, scanning for diagnosis using MRI relies on the assistance of injected dye to 




 An MRI scan alone does not determine prostate cancer; rather the scan merely 
identifies suspicious masses. Follow-up with a needle biopsy typically determines if the 
suspected abnormal mass is cancerous or not. The machine for MRI scans produces loud 
noises that could be damaging to patients.96 Additionally, the magnetic field generated is 
more than 10,000 times stronger than Earth’s core; it is imperative that patients harboring 
metal implants do not seek this method of scanning.96 Scanning by MRI is expensive and 
time-consuming in comparison to other methods available.  
2.2.4.3 Computerized Tomography 
A CT scan is a non-invasive medical procedure that utilizes x-rays for generation 
of internal gross anatomical structures. While a patient lies on his back inside of a CT 
machine, the patient is circles by a device that methodically passes x-rays through a 
patient’s diagnostic area of interest before collecting the x-rays as they exit the body.97 A 
collection plate mirrors and collects each x-ray passed through the patient, enabling 
measurement and interpretation scanned internal structures. Upon conclusion of the scan, 
superimposed images generate a 3-dimensional (3D) composite of the gland and possible 
masses present. Alternatively, adjacently aligned images generate composites of the 
gland and possible masses for a topographical view.  
The detection of abnormal tissue architecture that differs from normal tissue 
architecture less than 10mm in size, evades the sensitivity of CT scans.97 When scanning 
lymph nodes by CT, physicians have reported success augmenting sensitivity to almost 
70% and improving specificity to near 100% by employing size-detection limits coupled 




prognostic value when aberrations for detection exhibit higher density. Tissue masses of 
lower densities are not easily visible on a CT scan. A CT scan alone does not determine 
prostate cancer; rather the scan merely identifies suspicious masses. Follow-up with a 
needle biopsy typically determines if the suspected abnormal mass is cancerous or not. 
The use of positron emission tomography (PET) scans challenges the CT scan by 
enabling observation of metabolic activity of visualized masses. Both the CT scan and the 
PET scan rely on potentially damaging, ionizing radiation.94, 97 
2.2.4.4 Ultrasound  
During the medical procedure for an ultrasound, a transducer passes waves of 
sound through the diagnostic area of interest of a patient. Sound waves travel linearly 
through bodily cavities until striking the mass of an object. Sound waves reflected from 
the surface of objects with sufficient mass and return to the transducer. Emitting and 
receiving sound waves, a transducer relays information to a computer system that 
integrates, interprets and graphs perceived structures. Ultrasonic scans utilize high-
frequency waves that are inaudible to the naked human ear. The leading ultrasonic 
diagnostic tool used today is the transrectal ultrasound (TRUS). During this procedure, a 
patient lies on his side with his knees bent and drawn toward his chest. A medical 
practitioner inserts a transducer probe into the rectum, scanning until reaching the site of 
the prostate. A tissue biopsy enables further analysis if a suspicious mass is evident. 
Video and images obtained during the scan enable diagnostic evaluation post-scanning.  
Contrast-enhanced ultrasonography (CEUS) as well as ultrasound electrography each 




ultrasonic technology for the diagnosis of prostate cancer compared to more popular 
techniques used recently.100 The low positive-predictive value of TRUS alludes to the 
scans inability to detect small tumors when present.101 However, TRUS is sufficient for 
the detection of tumors overlooked by digital screening methods.101-102 Prognostic value 
enhances when TRUS accompanies needle biopsies.103 Medical complications that follow 
a TRUS scan are uncommon.  
2.2.4.5 Urine Flow Test 
Measurement of the efficiency of the bladder, sphincters and urethra better enable 
medical personnel to assess and identify possible abnormal functions in the overall 
physiology of the male urinary system as it pertains to prostate cancer. The bladder is a 
membranous sac that collects and stores liquid waste as urine until clearance from the 
body.  
2.2.5 Current Trends in Treatment 
 Current practices for the treatment of prostate adenocarcinoma vary greatly and 
factor into consideration the stage, aggressiveness or metastatic potential of the disease 
and patient medical history. Some of the more common treatments for prostate cancer 
include surveillance, androgen deprivation therapy, prostatectomy, cryotherapy, 
chemotherapy, radiation therapy, or combination therapy.  
2.2.5.1 Watchful Waiting 
During BPH or early-stage prostate cancer when the disease remains localized to 
a confined region, a medical staff may consult with the patient to advise a practice of 




the tumor cells prior to determining if invasive, costly or potentially risky 
recommendations of medical action is necessary to improve disease prognosis. Medical 
personnel employ active surveillance by tracking tumor status comparing PSA levels or 
cellular morphology and localization over time.104-105 
2.2.5.2 Androgen Deprivation Therapy/Hormone Therapy 
In early-stage prostate cancer disease while cancerous cells are still confined to 
the primary tumor, a medical staff may recommend castration of the androgen-producing 
teste and chemical ablation of androgen receptor signaling using androgen deprivation 
therapy (ADT) and chemical inhibitors specific to the androgen receptor.106-107 This 
practice attempts to abate the molecular driving force of androgen-dependent disease.106-
107  
2.2.5.3 Prostatectomy 
For men whose cancer remains localized and confined to the prostate but has 
spread throughout various regions of the organ, a medical staff may recommend surgery 
to remove the confined cancer cells during a radical prostatectomy.108-110 A prostatectomy 
attempts to remove the entire prostate gland. Men that undergo a radical prostatectomy 
may experience complications that lead to erectile dysfunction (ED), reduced sexual 
drive or incontinence among other symptoms.   
2.2.5.4 Cryoablation Therapy 
Under conditions during which cancer manifests in isolated masses localized to 
the prostate, a patient may receive cryoablation therapy.  Cryoablation therapy relies on 




cold temperatures.111-112 Upon freezing, cancer cells die without harm to adjacent, normal 
cells.111-112  
2.2.5.5 Radiation Therapy 
During localized, low-grade cancer, high-energy particles alone or in concert with 
hormone therapy function to kill cancer cells.113-115 Radiation therapy can capture lone 
cancer cells if surgical removal of the cancer fails to capture all of the cells.108, 116  
2.2.5.6 Chemotherapy 
For cancers that have metastasized or moved beyond the prostate, a medical staff 
typically employs intravenous or oral administration of anti-cancer pharmaceuticals that 
navigate the body and target remote cancer cells for death.107, 117 Unique to this treatment 
course is the ability of target-specific chemical agents to locate and discriminate against 
aberrant cells. The chemical agents employed exploit one or more molecular target 
expressed on the surface of tumors.  
Oftentimes in circumstances of metastatic disease, a medical staff may implement 
adjuvant care or treatments in tandem in order to maximize a patient’s prognosis and 
aggressively target remote and elusive cancer cells. There exists a variety of therapeutic 
treatments available designed to address each stage of prostate cancer, specific to time 
and status of disease upon diagnosis. Treatments for prostate cancer vary in levels of 
success, ranging from ineffective to total ablation of all clinically detectable cancer signs 
and symptoms. Whether applied in a hospital setting or at-home, each treatment for 




It is important to narrow the symptoms at presentation to clinic as to avoid over-
diagnosis of medical complications. Over-diagnosis can lead to unnecessary treatments 
involving costly, time-consuming, frightening, or even life altering medical procedures. 
Similarly, misdiagnosis as well as underdiagnoses can neglect the necessary medical 
required for timely intervention that could preserve the quality of life or life itself. Taken 
together, the patient and medical staff must work together in the decision making process 
to integrate information for the best prognosis possible for each patient. Each step of the 
screening, diagnostic, treatment and follow-up process requires the integration of 
accurate information for the most successful of patient outcomes. 
2.2.6 Prostate Cancer Cell Lines 
The prostate cancer cell lines used in this study represent the two overarching 
phenotypes of the disease, hormone-dependency and hormone-independency. The 
hormone-dependent LNCaP cell line established from cells isolated a needle aspiration 
biopsy of the left supraclavicular lymph node of a 50-year old Caucasian male.118 The 
hormone-independent PC3 cell line established from highly metastatic cells isolated from 
the lower lumbar of a 62-year old Caucasian male.119  
2.3 Protein Arginine Methyltransferases 
 Following protein biosynthesis, biological systems rely on molecular mechanisms 
that execute events of posttranslational modification (PTM) for the generation of more 
specialized proteins that augment the functionality of the mammalian proteome. The 
complex regulation of PTM events occurs as an interconnected, multilayered process 




range from cleavage or degradation of individual protein subunits or entire proteins to the 
transient addition of reversible covalent functional groups or proteins.121-122 Impacting a 
diverse range of cellular functions, PTMs regulate the cellular microenvironment 
throughout health and disease alike.123 Regulation of the cellular microenvironment by 
way of PTMs refers to one or more enzymatic or structural modifications by processes of 
phosphorylation, ubiquitination, acetylation, hydroxylation or methylation.120 While most 
events of PTMs manifests as events of phosphorylation, recent evidence suggests that 
protein methylation may be just as common.124 
2.3.1 Overview of Protein Methyltransferases  
The protein arginine methyltransferase (PRMT) family of nine enzymes 
orchestrates a plethora of PTMs affecting protein signaling, transcriptional regulation, 
RNA metabolism and DNA repair among other cellular processes as illustrated in Figure 
7.13, 125-131 Purified recombinant PRMTs evaluated in vitro express relatively low 
constitutive activity under normal conditions, suggesting basal activity may be required 
for normal metabolic functions. Canonically, PRMT5 associates with MEP50 as a 
member of the methylosome. A single PRMT5 molecule situates inside of a pocket of 
proteins that interacts with motifs unique to PRMT5. Mutant Jak2 was reported to disrupt 
the association of MEP50 and PRMT5 at PRMT5’s TIM barrel.18, 132-133 Events of post-
translational modification can function to alter the substrate specificity of PRMT 





Figure 7. PRMT5 regulates multiple biological mechanisms.131 Through events of symmetric dimethylation, PRMT5 
participates in the regulation of RNA processing, signal transduction and suppression or promotion of gene 
transcription through modification of the tails of histone proteins. 
Three structurally distinct sub-classes simplify classification of the 
methyltransferases according to the type of methylation pattern each carries out: Type I 
PRMTs are responsible for the generation of asymmetric dimethylarginine (aDMA); type 
II PRMTs are responsible for the generation of symmetric dimethylarginine (sDMA); 
type III PRMTs are responsible for the generation of asymmetric monomethylarginine 




similar across all subclasses with respect to the plane of symmetry about the length of 
recipient arginine residues.  
Protein arginine methylation is carried out by the transfer of one or more methyl 
groups from the methyl donor of S-adenosylmethionine (AdoMet) onto terminal (ω-
omega) guanidino nitrogen atoms of arginine residues on target substrates.135 Favorably 
positioned for interaction with hydrogen bond acceptors, the sidechain of the terminal 
arginine amino acid contains five unique protonated hydrogen atoms.  
In addition to arginine methylation, the other two major classes of protein 
methyltransferases are lysine and membrane-bound methyltransferases. The functional 
significance of methyltransferases is grouped and distinguishable according to their 
structural composition. The AdoMet-dependent methyltransferases are divisible by three 
classes. Class I methyltransferases harbor a seven-stranded β–sheet motif.135 Class II 
methyltransferases contain a SET lysine methyltransferase domain.135 Class three 
methyltransferases are the only known membrane-associated methyltransferases.135 
Characterized protein substrates methylated by PRMTs typically harbor motifs that are 
rich in glycine and arginine (GAR).131 Figure 8 provides a list of common substrates of 
PRMT methylation, by enzyme.131 Target substrates reported in literature are unique to 










Figure 8. List of PRMT substrates. A comprehensive list of known PRMT targets. Targets of PRMT methylation 
typically harbor a GAR motif. 
Each PRMT family member harbors a conserved core of motifs including a THW 
loop, I, post-I, II and III (Figure 9).136 The binding pocket for enzymatic activity is 






Figure 9. Domain homology of human PRMT enzymes.138 Comparison of PRMT family structural homology depicting 
conserved motifs and domains for functional diversity. 
 
The methylosome is a 20s cytosolic complex containing pICln (regulates the 
assembly of U1, U2, U4 and U5)139, spliceosomal snRNP, Sm core proteins, the WD 
repeat protein, WDR77/MEP50/WD45/p44 and PRMT5.140-142 In the cytosol, this 
complex executes the symmetric dimethylation of arginine residues on target substrates. 




2.3.1.1 Type I: Asymmetric Dimethylation 
Asymmetric dimethylation is the predominant type I PRMT of all methylated 
arginine residues to occur in mammalian cells.134, 143 As depicted in Figure 10, this class 
of enzymes asymmetrically deposits two methyl groups onto target substrates.144 Current 
literature suggests that all PRMT enzymes are first monomethylated prior to further 
modification and subsequent functional designations.145 Enzymes 1, 2, 3, 4, 6, and 8 are 
all type I PRMTs according to their enzymatic activity.15  
2.3.1.2 Type II: Symmetric Dimethylation 
Symmetric dimethylation is the predominant type II PRMT of all methylated 
arginine residues to occur in mammalian cells.146  
Figure 10. Generation of type methylation by protein arginines.2 Generation of type I asymmetric dimethylation, 




Type II PRMTs symmetrically deposit methyl marks onto target substrates as shown in 
Figure 10.2, 146 
Enzymes 5 and 9 comprise the only type II PRMTs given the pattern of methyl 
marks that they execute.15  
2.3.1.3 Type III: Monomethylation 
Each arginine methylation event may illicit different post-translational 
mechanisms to regulate biological events7. Type I PRMTs comprises PRMTs 1, 3, 4, 6 
and 8. Type II PRMTs comprises both PRMTs 5 and 7. PRMT 7 is also currently the 
only Type III PRMT discovered to date as depicted in Figure 10.2 
2.3.1.4 Protein Arginine Methyltransferase 5 
Originally discovered as the Janus Kinase-Binding Protein 1 (JBP1) or Jak2, 
PRMT5 is the predominant effector of symmetric deposition of most methylation marks 
in mammals.146 The functional product of PRMT5 is a 72kDa protein. Each molecule of 







Figure 11. PRMT5 ribbon structure.132 Ribbon structure of PRMT5 N-terminal and C-terminal domains. Depiction of 
substrate–binding sites. 
 
A molecule of MEP50 interacts with a molecule of PRMT5 through its TIM 
barrel shown in Figure 11.18, 132 Structurally, four PRMT5 molecules arrange adjacent to 
one another forming a tetramer; four MEP50 molecules externally flank the PRMT5 
tetramer. Evolutionarily conserved in humans and mice, PRMT5 and its ortholog are 
located on chromosome 14 according to the NCBI human genome sequence. Alternative 





Nine residues have been identified as necessary for maintaining the interaction 
between PRMT5 and MEP50.147 The hetero-octameric union of PRMT5 and MEP50 is 
approximately 453kDa.18 The catalytic site of PRMT5 adopts the canonical type I PRMT 
AdoMet binding domain.18, 143 The catalytic site of PRMT5 contains a SAM domain, a 
Rossman fold and a β–sandwich.18, 132 The SAM domain enables binding of both 
substrates and cofactors while the β–sandwich assists with substrate binding. The 
Rossman fold enables binding of nucleotides. Protein backbone interactions largely 
facilitate substrate interaction with PRMT5.18 The binding pocket of the PRMT5 active 
site contains a double-E loop that harbors two conserved residues, Glu435 and Glu444.143 
The glutamate residues 435 and 444 establishes salt-bridges with the guanidino side 
chains of substrate-arginines in preparation for the transfer of methyl group.148 
 Protein arginine methyltransferase 5 functions by catalyzing the monomethylation 
and symmetric dimethylation of target substrates.146 Symmetric dimethylation by PRMT5 
occurs in a mechanism of successive distribution, validated by the observation that events 
of dimethylated product occur at rates slower than events of monomethylated product.149 
A monomethyl peptide released from PRMT5 is recycled for carrying out the second 
methylation event generating a dimethylated product only after the concentration of 
monomethylated product exceeds the concentration of dimethylated products.149 
Mammalian PRMT5 requires tight association with MEP50 for catalytic activity.133, 150 
Regulation of the PRMT5-MEP50 complex was demonstrated by observation of 
phosphorylation at T5 on MEP50, by cyclin D1 – CDK4.151 The co-substrate, SAM 




PRMT5, the predominant type II protein arginine methyltransferase, was 
originally identified as a transcriptional repressor.146, 153 The regulation of gene 
expression is possible through PRMT5 methylation of histone tails. Histone substrates 
reported to be targets of PRMT5 methylation include H2AR3, H2R3, H3R8, and 
H4R3.144, 154-156 Chiefly, PRMT5 generates two patterns of methyl marks on target 
substrates: H3R8me2 and H4R3me2.157-158  
The majority of symmetric dimethylated protein substrates is resultant of 
regulation by PRMT5. Binding partners of PRMT5, including those appearing in Table 2, 
can alter the enzyme’s substrate specificity to effect methylation targets and biological 
signaling. Known PRMT5 binding partners include the chromatin remodeling complex 
SWI/SNF, RNA-binding protein Y14, methylosome adaptors RIOK1 and ICLN, histone-
binding protein cooperator CORP5 and HSP90.154-155, 159-161 
 
Table 2. Major PRMT5 interacting proteins.132 List of proteins that associate with 




MEP50 (Wdr77/P44) Essential for PRMT5 histone methylation 
pICln Contributes to spliceosome assembly and directs PRMT5 methylation to Sm 
proteins 
RioK1 Competes with pICln for PRMT5 binding and recruits nucleolin for 
methylation 
Menin/MEN1 Adapter protein for MML methyltransferase that targets PRMT5 to chromatin 
CoPR5 Mammalian nuclear protein that targets PRMT5 to chromatin  
hSWI/SNF Targets PRMT5 to chromatin and methylation of histone H3 
JAK kinases Mutant Jak2 found in leukemia phosphorylates PRMT5 and reduces its activity 
Blimp1 Localization of PRMT5 in primordial germ cells 
AJUBA Coordinates PRMT5 interaction with SNAIL 






2.3.2 PRMTs in Cancer 
 Overexpression and hyperactivity of each of the PRMTs has been reported 
in multiple cancer types. Dysregulation of canonical PRMT activity is achieved through a 
variety of mechanisms. Research suggests that hyperactivity of PRMT functions 
promotes the tumor microenvironment and perpetuates cancer progression. 
2.3.2.1 Type I Protein Arginine Methyltransferases  
The protein arginine methyltransferase PRMT1 has been observed to be 
hyperactive in multiple cancer types, correlating with disease.162 Asymmetric 
dimethylation of arginine 3 on histone 4 (H4R3me2a) results in transcriptional 
activation.163-164 In fact in prostate cancer, protein expression of PRMT1 correlates 
positively with tumor grade and accurately predicts recurrence.165 DNA repair proteins 
MRE11 and p53 binding protein 1 (p53BP1) appear to promote cancer phenotypes 
through dysregulated PRMT1 methylation.166 Inhibition of methyltransferases perturbs 
the p53BP1 response to damaged DNA.167 
 During events of PTMs, PRMT4 is phosphorylated in a process that eliminates its 
methyltransferase activity.168-169 However, overexpression of N-acetylglucosamine 
transferase (OGT) was reported to inhibit phosphorylation of PRMT4 at S217, 
subsequently enabling unregulated mitotic events.168-170 Acetylation of lysine 18 on 
histone 3 (H3K18ac) enables asymmetric dimethylation of at arginine 17 (H3R117me2a) 
of PRMT4.171-173 
 Methylation of the inner centromere protein INCEP by PRMT1 enhances the 




PRMT2 knockdown resulted in attenuation of cellular growth and migration.175 Silencing 
of PRMT6 in PC3 cells upregulated p21, p27 and CD44.176 PRMT6 overexpression 
impairs Histone 3 arginine 2 asymmetric dimethylation contributing to a global pattern of 
hypomethylation across DNA and correlates with cancer.177 Overexpression of PRMT8 
has been demonstrated to be correlated with breast, ovarian and gastric cancers.178 
2.3.2.2 Type II Protein Arginine Methyltransferases  
The dissociation of PRMT5 from MEP50 inhibits the methyltransferase potential 
of PRMT5.133 More specifically, regulation of the PRMT5-MEP50 complex was 
demonstrated by observation of phosphorylation at T5 on MEP50, by cyclin D1 – 
CDK4.151 Hyperphosphorylation of T5 on PRMT5 augments the methyltransferase 
activity of PRMT5, driving growth and proliferation of cells.179  
 Cytoplasmic localization of PRMT5 is correlated with growth and proliferation of 
LNCaP cells.25 Overexpression of PRMT5 in LNCaP cells generated greater rates of 
growth and proliferation.25 Inhibition of PRMT5 enzymatic activity alleviated growth and 
proliferation of LNCaP cells.25 PRMT5 protein expression was observed to elevated in a 
panel of lung cancer cells, compared to normal lung cells. Knockdown of PRMT5 
resulted in attenuation of A549 cells growth and proliferation.21 Inhibition of PRMT5 in 
vivo resulted in reduced tumor volume and mass.21 
 Elevated levels of PRMT5 protein is apparent in a variety of transformed cells. 
Knockdown of PRMT5 in transformed cells retards cellular growth while overexpression 
of PRMT5 correlates with high rates of proliferation.157, 180 The transition of cells from an 




expression. By way of an interaction with SNAIL the adaptor protein AJUBA, PRMT5 
enables downregulation of E-Cadherin.181 Loss of E-cadherin compromises the 
architectural integrity of polarized cells, enabling motile conditions. Silencing of PRMT5 
using siRNA also suppresses E-Cadherin. Cullin proteins (CUL4A and CUL4B) are 
adaptors for ubiquitination that enable the modification of protein function or signal for 
degradation. Hyperactivity of PRMT5 suppresses CUL4A and CUL4B, enabling 
neoplastic potential of cells.  
 For instance, PRMT5 catalyzes the symmetric dimethylation of p53, E2F1, RB, 
homeobox A9 (HOXA9) and RAD9.182-185 PRMT5 exhibits regulatory effects on 
opposite ends of the axis for epidermal growth factor receptor (EGFR)-RAS-ERK 
signaling. At arginine 1175, PRMT5 methylates EGFR, enabling phosphorylation of 
tyrosine 1173 to facilitate docking of SHP1.186 Inhibition of arginine 1175 methylation 
promotes growth, proliferation invasion and migration of mammary gland epithelial cells 
through hyperactive EGFR signaling.186 Alternatively, Melanoma cells treated with 
hepatocyte growth factor (HGF) augmented phosphorylation of MEK1, MEK2, ERK1 
and ERK2.187 Transcriptional suppression of tumor suppressor genes by PRMT5 
potentiates oncogenic perturbations and contributes to carcinogenic phenotypes. 
Hyperactivity of PRMT5 downregulates the expression of ST7 (correlated with autism) 
and NM23 (correlated with neuroblastomas) by symmetric dimethylation of arginine 8 on 
histone 3 (H3R33me2s).154  In myoproliferative neoplasms, phosphorylation of Jak2 lead 




PRMT5 effects biological functions by executing methylation of chromatin-
associated proteins and transcription factors, alike. Acetylation of lysine 9 of histone 3 
(H3K9ac) blocks PRMT5-mediated symmetric dimethylation (H3R8me2s).154 
Interestingly, acetylation of lysine 5 on histone 4 (H4K5ac) alters the methyl marks of 
motif H4R3 such that PRMT5 methylation suppresses H4R3 rather than PRMT1 
activating H4R3.158 Events of PTMs can function to influence crosstalk between protein 
arginine modification and histone proteins.  
 In cancers of the bladder, blood, breast, colon, lung, ovaries and prostate, PRMTs 
were reported upregulated or overexpressed.20-25 More research is required to develop 
novel mechanisms of therapeutic intervention that can function to induce remission and 
reduce disease progression. The evidence that links PRMTs to cancer is growing and 
strengthening as investigators continue to uncover the biological consequences of PRMT 
hyperactivity. The overwhelming observations of PRMT hyperactivity in multiple cancer 
types suggest that targeting one or more PRMTs may prove relevant for therapeutic 
intervention.  
2.3.3 PRMT Inhibitors 
 Arginine methylation has been evaluated under the auspice of small-molecule 
inhibitors. The only natural and global methyltransferase inhibitor identified to date, 
Sinefungin disrupts the methyltransferase activity of both lysine and arginine 
methyltransferases.188-189 Sinefungin is an analog to the AdoMet and restricts methylation 




including PRMT-mediated methylation. Hosts of other methyltransferase inhibitors have 
been discovered through screening techniques.  
 Eight compounds obtained from ChemBridge were identified by Wang et al. to 
interact with the substrate-binding site within PRMT5 to inhibit its methyltransferase 
activity. One (C9a) of these compounds demonstrated efficacy in vitro and in vivo to 
inhibit cellular proliferation, halt cellular growth and generated reductions in tumor 
volume and size.21, 25, 190 
 The small chemical inhibitor designed by Smil et. al, DS-437 competes for 
binding to the AdoMet to inhibit PRMT5 methyltransferase activity.191 This dual 
inhibitor inhibits the methyltransferase activity of both PRMT5 and PRMT7, but not 29 
other targets. DS-437 demonstrated its PRMT5-specific inhibition in the low micromolar 
range (6µM).190 
PRMTs have been shown to be upregulated in a number of different cancers and 
plays an essential role in growth of various cancer cells. 132, 192  Consistent with these 
observations, PRMT5-inhibitors suppressed growth of lymphoma, AML, and MCL cells 
in tissue culture. 193-195  More recently, EPZ015666 demonstrated antitumor activity in 
multiple MCL xenograft models. 195   
2.4 Plant-Based Medicine 
 Developed largely as mechanisms of defense against microbial threats, plants 
continue to evolve producing protective and adaptive strategies to promote self-
survival.196 People indigenous to an area often referred to nature to remedy their 




application of agents isolated from plants dates back throughout the millennia. 
Worldwide, more than 28,000 species of plants account for medicinal usage, while fewer 
than 16% of these plant species receive accurate references in publication.196 Despite the 
lack of documented pre-clinical or clinical research, the use of plants for therapeutic 
intervention and prevention of disease is gaining in popularity. The therapeutic value of 
responsibly administered plant-based medicine provides and potentiates efficacious relief 
from a variety of conditions including but not limited to disease of infection, deficiency, 
heredity, and physiology as well as the Human Immunodeficiency Virus (HIV).197-201 
2.4.1 Natural Alternatives to Chemotherapy 
Exposure to non-dietary environmental factors provide evidence of positive 
outcomes influencing the onset, management and prognosis of prostate cancer.78, 202 Oral 
administration of the chemical inhibitor, Finasteride in human clinical trials demonstrated 
a reduction in the prevalence-risk of prostate cancer by way of inhibiting the conversion 
of testosterone to dihydrotestosterone.202-203 Administration of the chemical, Dutasteride 
in human clinical trials reduced the risk of early-stage prostate cancer in comparison to 
control groups by way of inhibiting the conversion of testosterone to 
dihydrotestosterone.204 The naturally occurring inhibitors Finasteride and Dutasteride 
competitively inhibit 5α-reductase preventing the conversion of testosterone to 
dihydrotestosterone in a mechanism that reduces incident prostate cancer observed in 
short-term clinical trials.205 
Treatment of prostate cancer cells using Muscadine Grape Skin Extract (MSKE) 




sensitized cells to apoptosis via activation of PARP, caspases and the Unfolded Protein 
Response (UPR) in comparison to controls.206 Treatment of breast and prostate cancer 
cells using MSKE suppressed SNAIL1 expression and phosphorylation of STAT3, 
preventing Cathepsin L (CatL) expression and abrogated invasion and metastasis in 
advanced breast and prostate cancer cells.207  Chemical intervention using the 
antioxidant, MSKE administered to prostate cancer cells assisted Superoxide Dismutase 
(SOD) in reverting the aberrantly expressed profiles of E-cadherin and vimentin to near 
normal expression and reverted the pro-cancer effects of EMT and Reactive Oxygen 
Species (ROS) by targeting overexpressed SNAIL1.208 Evaluated in randomized human 
clinical trials, MSKE did not demonstrate significant effects for lowering values of 
classical prognostic markers used in prostate cancer detection.209-210 
Advanced prostate cancer cells treated with the phytoalexin, camalexin, 
experienced a reduction in viability and an induction in apoptosis, mediated through ROS 
generation.211 In comparison to primary epithelial and hormone-dependent prostate cells, 
camalexin did not exhibit similar results.211 Although the exact mechanism has to be 
determined, camalexin selectively antagonized metastatic prostate cancer cells through a 
ROS-dependent mechanism.  
2.4.2 Dendrobium aurantiacum ver. denneanum  
The flowering Orchidaceae (orchid) plant, D. denneanum, is native to the 
southern provinces of China and the western Himalayas.212 This orchid congeneric grows 
robustly in the Sichuan province and does not require protection from cultivation. The 




More than 1000 species of plants comprise the genus Orchidaceae. Southern 
China was once home to more than 74 species of wild Dendrobium.213 Resultant of 
overharvesting to meet the growing interest of clinical trials, many species of 
Dendrobium appear on national or international lists of endangered plants. The five 
endangered species most notable for owning the medicinal benefits ascribed to 
Dendrobium known colloquially as “Shi Hu,” and their congeneric relatives appear in the 
2010 Chinese Pharmacopoeia.214 Traditional Chinese medicinal practices relied on Shi 
Hu for ailments of imbalance rumored to replenish yin. Contrary to popular trends in the 
use of botanicals for medicinal application, Shi Hu relies on the stems of orchid plants 
rather than the flower petals or leaves.215   
Previous experimental evaluations of the plant source D. denneanum yielded 
more than 20 secondary metabolites possessing some medicinal value for the prevention 
of inflammation, fever, aging and macular degeneration.214, 216 The compound, Gigantol 
isolated from D. denneanum suppressed gene expression to inhibit the formation of 
galactose-induced cataracts in rats.217 A phenolic glycoside from D. denneanum selected 
against acute myeloid leukemia cells but not control cells and antagonized glutamate to 






Figure 12. Dendrobium denneanum. (A)   Fully grown and labeled D. denneanum (B) Traditional methods of 
consumption of D. denneanum including tea, broth and stew, from top to bottom, respectively. (C) Image of D. 






EXPERIMENTAL METHODS AND TECHNIQUES 
 
3.1 Cell Culture 
Adherent monolayer cultures of androgen-dependent and androgen-independent 
human LNCaP and PC3 prostate cancer cell lines obtained from the American Type 
Culture Collection (ATCC) from were maintained in Roswell Park Memorial Institute 
(RPMI) 1640 medium from Gibco by Invitrogen (31800-089) completed by 
supplementation with 10% FB Essence (FBE) from Seradigm (3100-500), 1% L-
Glutamine from Gibco by Invitrogen (25030-081) and 100mM Penicillin/Streptomycin 
from Corning (30-002Cl) in Corning T-75 flasks (430641). Cell lines were grown at 
37°C in humidified atmospheric conditions of 5% CO2. Cell culture media was 
replenished every third day after washing using 1x phosphate buffered saline (PBS). 
Once LNCaP and PC3 populations reached near-confluence, cells were split 1:3 and 1:6, 
respectively.  
3.2 Growth Assay 
LNCaP and PC3 cells were seeded into Nunclon ∆ Surface 24 well-plates 
(142485) at 1.0x104 and 6.0x103 cells per well respectively and permitted to attach 




replaced using RPMI 1640 supplemented with 2% FBE. Experimental cells 
received titrations of crude or purified plant extracts. Control cells received DMSO, 
determined by and equivalent to the largest volume of plant extract utilized for 
treatments. Cell lines were grown for 72 hours at 37°C in humidified atmospheric 
conditions of 5% CO2. Cells were harvested using Trypsin-EDTA from Sigma (T4174). 
In a microcentrifuge tube, a subpopulation of cells was reconstituted into an equivalent 
volume of RPMI1640 and Trypan Blue Solution (Sigma T8154) stain and counted 
manually using a hemocytometer.   
3.2.1 Cell Counting Using a Hemocytometer  
Hemocytometer chambers were stored while submerged in at least 70% ethanol 
prior to use. Air-dried chambers were positioned on a flat surface prior to loading and 
covered using a hemocytometer glass coverslip carefully positioned atop of the chamber 
for counting. A 20µL aliquot of treated or untreated cell suspension was introduced into 
the loading chamber of a hemocytometer using a suitable pipette. Cells appearing on or 
beyond the boundary lines of any quadrant were excluded from observed cell counts. 
These cells were not counted. Similarly, cells appearing within the boundary lines that 
denote the cross-structure were omitted from observed counts. These cells were not 
counted. Only cells appearing definitively within quadrants 1, 2, 3, or 4 were observed 
for counts. After counting, each hemocytometer chamber and accompanying coverslip 
was cleared of cells by manual wiping with a ChemWipe containing 70% ethanol and 




3.3 Cell Cycle Analysis 
LNCaP and PC3 cells were seeded into 100mm VWR Tissue Culture Dishes 
(10062-880) at 4.8x105 and 2.4x105 cells per dish, respectively. Cells were permitted to 
attach overnight. On the following day, cells were washed using 1xPBS and culture 
medium was replaced using RPMI 1640 supplemented with 2% FBE. Experimental cells 
received titrations of crude or purified plant extracts. Control cells were treated with 
DMSO determined by and equivalent to the largest volume of plant extracts utilized for 
treatment. Cell lines were grown for 72 hours at 37°C in humidified atmospheric 
conditions of 5% CO2. Media containing concentrations of treatments were removed 
using needle-aspiration. Cells were washed using cold 1xPBS. Dishes containing cells 
and PBS were placed on ice to limit protein degradation due to ambient temperatures. 
While in 1xPBS, cells were harvested manually by gently detaching the monolayer of 
cells and transferred to pre-chilled 15-mL conical tubes. Cells were pelleted using a 
desktop centrifuge at 4ºC, 0.6xRCF, for 2 minutes. Supernatants were removed by 
pipetting. Cells were resuspended into 100µL of cold 1xPBS. Under gentle vortexing 
exercising caution not to lyse cells, each sample of cells received 3mL of cold 70% 
ethanol. Cells were incubated overnight in 70% ethanol and 1xPBS at 4ºC.  
On the following day at room-temperature (RT), cells were pelleted using the 
conditions previously describe with a desktop centrifuge. Supernatants were removed by 
pipetting. Cells were resuspended into Propidium Iodide (PI) solution (10µg/mL final 




microcentrifuge tubes and incubated for 20 minutes at RT. After 20 minutes, samples 
were transferred to ice and protected from white light until same-day analysis using the 
Accuri C6 Flow Cytometer.  
3.4 Proliferation Assay 
3.4.1 Preparation of Coverslips  
Glass coverslips were prepared inside of a class II sterilized biological safety 
cabinet. One coverslip for each well of Nunclon ∆ Surface 6 well-plates (140675) was 
incubated at RT for 15 minutes in 100% EtOH then permitted to air-dry from a vertical 
position. Coverslips were then subjected to one round of ultraviolet light for 15 minutes. 
Coverslips were placed squarely into individual wells of the 6 well-plates. Coverslips 
were carefully handled using forceps for the duration of the entire time for preparation.  
3.4.2 Bromodeoxyuridine (BrdU) Incorporation Assay 
LNCaP and PC3 cells were seeded onto coverslips in 6 well-plates at densities of 
1.5x106 and 2.5x106 cells per well, respectively, in RPMI 1640 complete medium as 
described  the Cell section. After 24 hours, medium was removed and cells were washed 
twice using 1 x phosphate buffered saline (PBS), before replacing media with fresh RPMI 
(+2%FBE) with dissolved Dimethyl Sulfoxide (DMSO) or plant extracts. Control cells 
received DMSO, determined by and equivalent to the largest volume of plant extract 
utilized for treatments. Experimental cells received a titrated range of crude or purified 




hours. Cells were then washed using 1x PBS and replenished with fresh RPMI media 
containing BrdU (Beckton Dickinson Biosciences 247580). Cells were incubated for 2 
hours with BrdU (10µM) and immunostained using anti-BrdU (1:400) antibody (Beckton 
Dickinson Biosciences) with strict adherence to a protocol published previously.25 
Coverslips were then relocated onto appropriately charged, labeled, clean slides in final 
preparation for microscopy. Cells were imaged using a Carl Zeiss Confocal-LSM 700 
Microscope.  
3.5 Minimum Inhibitory Concentration (IC50) 
LNCaP and PC3 cells were seeded into Nunclon ∆ Surface 24 well-plates 
(142485) at 1.0x104 and 6.0x103 cells per well respectively and permitted to attach 
overnight. Cells were washed using 1xPBS. On the following day, culture medium was 
replaced using RPMI 1640 supplemented with 2% FBE. Control cells received DMSO, 
determined by and equivalent to the largest volume of plant extract utilized for 
treatments. Experimental cells received a titrated range of crude or purified plant extracts. 
Triplicates of experimental cells received titrations of crude or purified plant extracts. 
Cell lines were incubated for 72 hours at 37°C in humidified atmospheric conditions of 
5% CO2. Medium was removed using needle-aspiration. Cells were washed once using 
1x PBS. Cells were harvested using Trypsin-EDTA. In a microcentrifuge tube, a 
subpopulation of cells was reconstituted into an equivalent volume of RPMI1640 and 
Trypan Blue Solution stain and counted manually using a hemocytometer. Minimum 




concentration at which half of the seeded population of cells remained viable at 
calculated between fold-change ranges of crude or purified compounds. Data sets were 
analyzed and graphed using Microsoft Excel. 
3.6 Protein Isolation and Quantification 
Protein samples were isolated using cell scrapers and 1x protein Passive Lysis 
Buffer (PLB) (Promega E194A), supplemented with Phosphatase Inhibitor Cocktail 
(Santa Cruz 45044) and Protease Inhibitor Cocktail (Active Motif 100510) for total 
protein. Protein concentrations were ascertained using the Protein Assay Dye Reagent 
Concentrate (Bio-Rad 500-0006), Bovine Serum Albumin (BSA) (New England BioLabs 
B9001S) and the Bradford Assay of the DU800 Spectrophotometer (Becton Coulter). 
Standard concentrations used were 1, 2, 3, 4 and 5µg/mL. Standards and samples were 
measured in triplicate with each coefficient R value ≥ 0.998.  
3.7 Western Blot Analysis 
Protein samples were resolved using sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). Protein samples were transferred overnight at low voltage 
(~6000mV) to a nitrocellulose (NC) membrane. In order to reduce the potential for non-
specific antibody interaction, NC blots were blocked for 30 minutes at room temperature 
using 3% non-fat milk (Santa Cruz 2324) in 1 x Tris-Buffered Saline Tween20 (TBST) 
while shaking at low speeds. Primary antibodies were reconstituted into 2% BSA in 1x T-
BST. Blots were incubated in a primary antibody for 2 hours at room temperature while 




moderate speeds over 5 minutes with each wash. Secondary antibodies were reconstituted 
into 2% BSA in 1x TBST. Blots were incubated in a secondary antibody conjugated with 
HRP at room temperature for 1.5 hours while shaking at low speeds. Blots were then 
washed 4 times, each in 5 minute increments using 1x TBST. Protein bands were 
visualized using an enhanced chemiluminescence substrate (PerkinElmer 
NEL103001EA) according to specifications recommended by the manufacturer. 
Densitometry was used to determine the relative concentrations of target protein as 
normalized according to β-actin for use as an internal standard.   
3.8 Antibodies 
Anti-dimethyl-arginine, symmetric (SYM10) (07-421) polyclonal rabbit antibody 
was obtained from EMD Millipore. BrdU (247580) antibody was obtained from Beckton 
Dickinson Biosciences . Anti-β-Actin (A2103) polyclonal rabbit antibody was obtained 
from SigmaAldrich. Anti-BrdU (347580) was obtained from Beckton Dickinson 
Biosciences. 
3.9 Radio-Labeled Protein Methylation Assay 
Experimental samples were prepared using various concentrations of plant 
extract, 1µg of SmD3, PRMT enzyme (0.2µg of PRMT1, 0.2µg of PRMT3 or 0.8 µg of 
PRMT5), BSA, and H2O to volume. Positive control samples were prepared using 
DMSO, SmD3, PRMT enzyme (0.2µg of PRMT1, 0.2µg of PRMT3 or 0.8 µg of 
PRMT5), BSA, and H2O to volume. Positive control samples lack an inhibitor of 




BSA, and H2O. Negative control samples lack a PRMT enzyme to execute 
methyltransferase activity.  
Reactions (40µL total volume) were initiated with the addition of a reaction 
mixture containing reaction buffer (0.5M Tris-HCL, pH 7.5, 10mM EDTA, 10mM 
EGTA, 0.1M DTT, 10mM SAM, 1µCi of S-[methyl-H3] adenosylmethionine 
(PerkinElmer) and H2O) and were incubated at 30°C for 2 hours. Reaction samples were 
analyzed utilizing one of the two following methods:  
3.9.1 Analysis by SDS-PAGE 
Reaction samples for analysis using SDS-PAGE were terminated with the 
addition of 10µL of 5x SDS sample reducing buffer. The final concentration of SDS in 
50µL of total sample (40µL of sample + 10µL of 5x SDS) is 1x. Samples were incubated 
at 95ºC for five minutes using a heat-block. Samples were separated using 15% gels over 
100V of electricity. Gels were fixed for 30 minutes in 50% water, 40% methanol and 
10% acetic acid (v/v/v), incubated in Amplify (Amersham by GE Healthcare) for 10 
minutes. Fixed gels were immobilized onto filter paper, positioned on the surface of dried 
a gel dryer (BioRad model 583) and covered with generic plastic wrap. Gels were dried 
and affixed to filter paper for 2 hours at 80ºC. Using a dark room, dried gels were 
exposed to X-ray film (Phenix F-BX57) and stored inside of a radiographic cassette. 
Cassettes were stored at -80˚C for ≥15 hours. After the incubation period for film 
exposure, cassettes were removed from the -80˚C and allowed to come to room 




Films were scanned using a ChemiDoc Imager XRS+ system. Values of IC50 were 
calculated by densitometry. Results were analyzed and graphed using Microsoft Excel.  
3.9.2 Analysis by Liquid Scintillation 
Reaction samples to be analyzed using scintillation were spotted onto DE81 
Whatman Paper Discs. Spotted discs were washed 3x using NaHCO3 at 5 minutes each, 
decanting solutions after each wash. Next, spotted discs were washed 1x using H2O at 5 
minutes and then spotted discs were washed 1x using 100% ethanol. Discs were 
permitted to air-dry overnight. The following day, dried discs were transferred into 
separate scintillation vials using forceps. Each scintillation vial received an aliquot of 
5mL of ScintiVerse BD Cocktail (SX18-4) scintillation solution. Samples were analyzed 
by scintillation counts for H3 over 1 minute in a Beckman Coulter LS 5000 TD 
Scintillator Counter. Results were analyzed and graphed using Microsoft Excel.  
3.10 Real Time – qPCR 
Total RNA was isolated from cells using the TRIzol reagent (ThermoFisher). 
Strands of cDNA were generated using the Superscript III First-Strand Synthesis System 
(ThermoFisher). Real-time PCR was performed with Go-Taq qPCR master mix 
(Promega) and specific primers (40 cycles of 15 seconds at 95°C and 20 seconds at 




mean expression levels of the target genes were calculated using the comparative CT 
method (RUN; 2-ΔCT).  
3.11 Protein Expression and Purification 
 According to previously used methods, PRMT 1, PRMT3, PRMT5 and SmD3 
cDNAs were subcloned into pET15b vectors purchased from Novagen and transfected 
into BL21 (ED3) competent E. coli cells.190 Amino-terminal His (6x) tagged proteins 
were expressed and purified using Ni-NTA Agarose (Qiagen) as reported previously.25 
Proteins were separated across 10% SDS-PAGE gels. Proteins were detected using 
Coomassie Blue R-250 Stain for 2 hours. Gels were destained while washing in water, 
methanol and acetic acid 50/40/10 (v/v/v) for 15 hours. Recombinant human histone H4 
and H2A proteins were obtained from SigmaAldrich. 
3.12 Organic Extraction  
Sun-dried and packaged spikes (stems) of Dendrobium aurantiacum var. 
denneanum were purchased and shipped from the Taipei Orchid Farm in China. Products 
were shipped in sealed plastic packages or airtight glass containers. Magnolia leaves and 
pods were pruned from live trees growing on the campus of Clark Atlanta University. 
Collected leaves and pods were air-dried in the laboratory on the lab bench at room 
temperature over 48 hours. Pre-packaged, whole Fennel Seeds were purchased from the 
Great Wall Supermarket located at 2300 Pleasant Hill Road, Duluth GA, 30096, USA. 
Plant materials (100g) were pulse-grounded into medium parts using a commercial Lab 




excessive generation of heat as to avoid damage to plant materials. Medium parts were 
generated in order to maximize the surface-to-volume ratio of plant material to extraction 
solvent.  
Extractions were initiated by incubating 1L of H2O, ethyl acetate (EtAc) or 
Tetrahydrofuran (THF) alone with slow or gentle agitation to suspend solid plant 
materials. Crude compounds were extracted from plant materials at 4, 26 and 50°C. 
Crude compounds were extracted from plant materials over 24, 48 and 72-hour time-
courses. Supernatants containing crude extracts of plant materials were separated from 
whole plant materials using a separatory funnel. Solid-plant materials were discarded; 
liquid crude extracts were collected and retained.  
3.12.1 Water Extraction 
Crude extracts were extracted against H2O using vigorous shaking for 
approximately 5 minutes. Separation of the aqueous phase (H2O) from the organic phase 
(EtAc) was facilitated using a Beckman Coulter J-E floor centrifuge at 5000rpm over 5 
minutes at room temperature with rotor F-10. Extraction by water was repeated twice 
more for samples of EtAc containing crude plant materials. Both aqueous and organic 
liquid samples were immobilized by submerging glass bottles for lyophilization into 
liquid nitrogen. Samples were dried using a FreeZone 4.5 Liter Benchtop Freeze Dry 






3.12.2 Hexane Extraction 
 Dried samples of crude extracted materials were reconstituted into 15-25mL of 
Methanol (MeOH). Reconstituted samples were extracted against equal volumes of 
hexane or cyclohexane using vigorous shaking for approximately 5 minutes. Separation 
of the aqueous phase (MeOH) from the organic phase (hexane or cyclohexane) was 
facilitated using a Beckman Coulter J-E floor centrifuge at 5000rpm over 5 minutes at 
room temperature with rotor F-10. Extraction by hexanes was repeated twice more for 
samples of MeOH containing crude plant materials. 
Both aqueous and organic liquid samples were immobilized by submerging glass 
bottles for lyophilization into liquid nitrogen. Samples were dried using a FreeZone 4.5 
Liter Benchtop Freeze Dry System by Labconco. Methyltransferase inhibitory potential 
was evaluated using radiolabeled protein methylation assays as mentioned previously, at 
each step along the extraction process. 
3.13 Chromatography  
Both the Xterra 125Å, 3.5µm, 3.9mm x 100mm and the Xterra 125Å, 10µm, 
7.8mm x 150mm C-18 preparatory columns for reverse-phase chromatography were 
purchased from Waters. Dried samples from extraction were reconstituted into 5mL of 
EtAc. Samples were aliquotted evenly among 5x microcentrifuge tubes that were pre-
massed. Aliquotted samples were dried using a FreeZone 4.5 Liter Benchtop Freeze Dry 
System by Labconco. Dendrobium samples were separated over 80 minutes, 




Fennel or Magnolia was separated over 80 minutes, incrementally increasing the buffer 
MeOH from 10% to 100%. Both Fennel and Magnolia samples were separated using 
0.1% trifluoroacetic acid (TFA), total volume.  
Dried Dendrobium samples were reconstituted into 40% acetonitrile (AcN) by 
volume. Dried Magnolia or Fennel Seeds were reconstituted into MeOH with 0.1% 
trifluoroacetic acid total volume. For analytical determination of peak-fraction resolution, 
50-200µL volumes of sample were loaded onto a Shimadzu Ultra-Fast Liquid 
Chromatography apparatus. For mass preparation of peak-fraction collection, 2mL of 
sample were loaded onto the high-pressure liquid chromatography (HPLC) machine. 
Peak-fractions eluted from the HPLC were collected manually using microcentrifuge 
tubes or graduated sample collection tubes. Samples for empirical analysis were 
transferred to pre-massed microcentrifuge tubes and dried using a desktop SpeedVac to 
immobilize liquid samples, connected to the FreeZone 4.5 Liter Benchtop Freeze Dry 
System by Labconco.  
Each sample collected for mass-preparation was transferred to individual 50mL 
conical tubes designated by peak-fraction and dried using the FreeZone 4.5 Liter 
Benchtop Freeze Dry System by Labconco. Each 50mL conical tube was snap-frozen by 
submerging capped tubes into liquid nitrogen to immobilize contents. After contents were 
frozen, caps were replaced with plastic wrap anchored by rubber bands around the sides, 




introduced into the plastic covering of each sample using a sterile syringe, changed with 
each utilization.  
3.14 Mass Spectrometry 
Electrospray Ion-Mass Spectrometry was facilitated by Simian Wang and her 
Department of Chemistry staff in the Natural Science Center at Georgia State University. 
3.15 Chemicals and Reagents 
HPLC-grade of the following reagents: Ethyl Acetate (E195-4), Methanol (A412-
4), Water (W5-4) and Acetonitrile (BDH 83639.400) were acquired from 
FisherScientific, Inc.  FB Essence by Seradigm was purchased from VWR.  
3.16 Statistical Analysis 
All experiments were validated by obtaining similar results from a minimum of 
three independent, empirical evaluations. Data reported are represented by the mean of 
three independent experiments ± the standard deviation. A 2-tailed, unpaired, student t-
test was used to determine whether differences between control and experimental 
samples were statistically significant. For these studies, statistical significance was 








4.1 Overview of Extraction Protocol 
 It has been reported that a variety of plants and plant derivatives harbor agents that 
possess chemotherapeutic and anti-tumorigenic properties. We began our investigation by 
determining whether PRMT5-inhibitory compounds could be extracted from Dendrobium 
plants. Several species of orchids have been documented for having demonstrated anti-
microbial and anti-tumorigenic activity. We extracted compounds from the stems of dried 
orchid plant, Dendrobium aurantiacum var. denneanum as shown in Figure 13.  
 
Figure 13. Organic extraction of D. denneanum. Crude plant materials were extracted using organic reagents. The 
initial extraction used EtAc to liberate crude extracts. Polar compounds were excluded by extracting EtAc against H2O, 




Using D. denneanum, we attempted to extract a source of chemical constituents 
possessing methyltransferase inhibitory potential for use against PRMT5. Dried stems of 
D. denneanum were extracted with water, ethanol, methanol or ethyl acetate. Extractions 
of D. denneanum were carried out at temperatures of up to 50ºC for periods of up to 72 
hours. The solvents ethanol, methanol and ethyl acetate extracted chemical constituents 
that exhibited inhibitory activity against PRMT5. Water as a solvent did not extract 
PRMT5-inhibitory chemical constituents from D. denneanum.  
We also attempted to obtain PRMT5-inhibitory chemical constituents from a 
relative of D. denneanum, Dendrobium nobile (D. nobile) by extraction. Attempts to 
extract chemical compounds from D. nobile using organic reagents of ethanol, methanol 
or ethyl acetate, but not water yielded PRMT5-inhibitory chemical constituents. 
Extractions of D. nobile were conducted under the same time and temperature parameters 
as those used for D. denneanum. The organic extraction of each species of Dendrobium, 
yielded chemical constituents that exhibited inhibition against PRMT5 methyltransferase 
activity. We selected ethyl acetate as the extraction solvent of choice for further analysis 
of D. denneanum (Figure 13).  
After separation of supernatant from the plant pellet, the liquid extract product 
suspended in ethyl acetate was separated by water partition. Water partition of the plant 
extract in ethyl acetate was carried out three times in effort to remove water-soluble 
components from the extract. The dried extract was dissolved into methanol and partitioned 





4.2 Optimization of Extraction Conditions for D. denneanum Extract.  
 Next, we wanted to determine the best conditions necessary for the extraction of 
D. denneanum compounds. Using ethyl acetate, ground D. denneanum was extracted 
while varying time and temperature conditions. D. denneanum was extracted at 
temperatures of 4, 25 and 50ºC. Dendrobium was extracted over periods of 24, 48 and 72 
hours. As shown in Figure 14, the extract of Dendrobium at 25º over 72 hours possessed 
the greatest fraction of phytochemical compounds as measured assessing 
methyltransferase activity. 
 
Figure 14. Time and temperature-dependent extraction of Dendrobium d. Crude compounds from D. denneanum were 
extracted while varying time and temperature in order to optimize extraction conditions for methyltransferase-
inhibitory compounds. Methylation or inhibition of methylation for the substrate, SmD3 was assessed by protein 
methylation assay and radiolabeled isotope, H3. 
The yield of PRMT5-inhibitory product obtained from the crude extract was calculated to 
be approximately 0.1% (Figure 14). This was designated the crude extract. 
4.3 Determination of PRMT-enzyme selectivity. 
 A radiolabeled methyltransferase assay confirmed enzyme-specific inhibitory 
potential of extracted compounds against methylation of the SmD3 substrate (Figure 15). 




PRMT activity, we assessed the methyltransferase activity in vitro, in the presence and 
absence of D. denneanum titrations. 
 
Figure 15. D. denneanum selectively inhibits PRMT activity. (A) Assessment of methylated SmD3 in an in vitro assay 
using titrations of D. denneanum. crude extract against type I, II and III PRMTs. (B) Determination of minimum D. 
denneanum required for PRMT5 inhibition, in vitro. 
In a concentration-dependent manner, Dendrobium exhibited varied inhibition of 
the SmD3 product of all types of PRMTs (Figure 15A). More interesting, crude 
Dendrobium selectively inhibited the type II methyltransferase activity of PRMT5 the as 
compared to type I and type II PRMTs, depicted in Figure 15. Although levels of 
methyltransferase inhibition were detected, D. denneanum inhibited type II 
methyltransferase activity (Figure 15A, PRMT5) more thoroughly than type I 
methyltransferase activity (Figure 15A, PRMT1 and PRMT3). 
Further analysis of D. denneanum extract against the type II methyltransferase 
PRMT5, revealed potential for inhibition in the microgram-range of compound, as shown 




PRMT1, PRMT3 and PRMT5 with the IC50 values of 70, 90 and 15 mg/mL, respectively 
(Figure 15). 
4.4 Isolation and purification of D. denneanum crude extract 
4.4.1 Separation and Purification of Individual Compounds. 
In order to isolate individual compounds from the crude extract of D. denneanum, 
samples were further separated using chromatography (Figure 16A).  
 
Figure 16. Separation of compounds from crude Dendrobium denneanum. (A) Crude materials extracted from D. 
denneanum. were separated using reverse-phase chromatography using a gradient of AcN over 80 minutes. (B) In vitro 




With HPLC, the crude extract was further separated using a linear gradient of 
acetonitrile from 10-100% in water. Peaks eluted from the column were collected and 
dried under vacuum (Figure 16A). An in vitro methylation assay indicated that 4 peaks 
(P2, P3, P4 and P5) depicted in figure 16 with retention times ranging from 50 minutes to 
57 minutes, contained PRMT5-inhibitory chemical constituents. The four peak-fractions 
obtained and analyzed differentially inhibited SmD3 methylation by PRMT5.  
Using the same buffer conditions for with HPLC, D. nobile was separated. As 
shown in Figure 17, two PRMT5-inhibitory chemical constituents were collected from 
the eluate. 
Peak-fractions 35, 54 and 56 of D. nobile demonstrated significant inhibitory 
potential against PRMT5-methyltranferase activity (Figure 18). Peak-fractions eluted from 
Figure 17. Separation of compounds from Dendrobium nobile. Crude materials obtained from the orchid, D. nobile 
were separated using a revere-phase column. Compounds were separated over 80 minutes of an incrementally 




the column during times ranging from 51 to 57 minutes. Peak fractions 35, 54 and 56 
demonstrated selective inhibitory activity against type II methyltransferase activity but not 
type I methyltransferase activity as shown in Figure 18 A and B. Peak-fraction 3 exhibited 
the greatest level of PRMT5 inhibition as compared to other peak-fractions separated from 
D. denneanum (Figure 16B). Peak-fraction 3 was selected for further analysis. 
 
4.4.2 Purity of Compounds Isolated from D. denneanum  
After verifying PRMT5-inhibitory potential of multiple compounds isolated from 
crude D. denneanum, we sought to measure the level of purity of each compound. Four 
Figure 18. Dendrobium nobile inhibits PRMT5 activity. (A) Analysis of SmD3 methylation by PRMT5 after 
exposure to peak-fractions purified using reverse-phase chromatography. (B) Analysis of SmD3 methylation by 




peak-fractions obtained from D. denneanum demonstrated potential for inhibition of 
PRMT5 methyltransferase activity. Peak- fraction 2 (lane 5) exhibited poor resolution as 
depicted in Figure 16A. We rationalized that the inhibitory results observed for this peak-
fraction 2 was likely due to a combination of multiple compounds present in one peak-
fraction. Additionally, the elution volume of peak-fraction 2 was nearly negligible in 
comparison to other peak-fraction volumes. 
 
Figure 19. Determination of purity of peak-fraction 3. Assessment of purification of compound 3 separated from D. 
denneanum using ESI-MS analysis. 
We did not seek to measure the purity of this peak-fraction.  Peak-fractions 3, 4, and 5 
were outsourced for electrospray ion mass spectrometry analysis (ESI-MS) at the Georgia 
State University. As shown in Figure 19, peak-fraction 3 was purified to 100%, with a 
molecular weight of 592.2766 Daltons (Figure 19).  
Mass-spectral analysis resolved a single compound present in peak-fraction 3. 
Two isoforms of peak-fraction 3 were also identified at 593.2797 and 594.200 Daltons 




The two compounds from D. nobile exhibitig the strongest inhibition of PRMT5 
activity were subjected to mass spectrometry analysis. Peak-fraction 54 was purified to 
100% with a molecular mass of 428.210 Daltons (Figure 20). Peak-fraction 56 was purified 
to 100% with a molecular weight of 536.16 Daltons (Figure 20). Multiple compounds were 
obtained from two different species of Dendrobium demonstrating inhibitory potential 
against PRMT5 activity.  
4.5 Purified Compounds’ IC50 Values 
4.5.1 D. denneanum compounds in vitro IC50  
 To assess the functional concentration of compound required to inhibit protein 
arginine methyltransferase enzymatic activity without competition, we conducted in vitro 
analyses, verified using protein methylation assays. As shown in Figure 21, each compound 
(P2, P3 and P4) demonstrated concentration-dependent inhibition of SmD3 methylation by 
types I and II protein arginine methyltransferases, as compared to controls.  Compound 5 
least-inhibited PRMTs as compared to other compounds. Compound 4 demonstrated 
Figure 20. Determination of purity of peak-fractions p54 and p56. Mass determination of compounds p54 and p56 




slightly less effectiveness against PRMTs than compound 3. The compound in peak-
fraction 3 demonstrated the greatest level of inhibition for methylation of SmD3 by all 
protein arginine methyltransferases as shown in Figure 21 with an IC50 of 0.2µg/mL 
(0.3µM). Concentrations of compounds required for inhibition of methyltransferase 
activity were calculated by measuring SmD3 methylation using densitometry. 
 
 
Figure 21. Determination of in vitro minimum enzyme inhibitory values. Determination of the required minimum 
concentration of compounds purified from D. denneanum against type I, II and III PRMTs for inhibition of SmD3. 
Analyses were carried out using a cell-free assay.  
4.5.2 Determination of purified D. denneanum in vivo IC50 values. 
 To test whether the purified compounds could inhibit protein methyltransferase 




such, we subjected prostate cancer LNCaP and PC3 cells to titrations of D. denneanum 
compounds. Figure 22A displays the concentration-dependent inhibition of prostate cancer 
cell growth achieved independently using compounds P2, P3, or P4. Values of 
concentration required for enzyme inhibition were determined by cell counting.  
 
Figure 22. Dendrobium denneanum diminished cell growth but not PRMT5 protein. (A) Assessment of cell growth 
after treatment with crude D. denneanum. (B) Relative protein expression levels of PRMT5 and Wdr77 after treatment 
with crude D. denneanum. 
During determination of the IC50 values, we noticed that the compounds strongly 
reduced cell growth of both LNCaP and PC3 prostate cancer cells, but did not alter 





4.6 D. denneanum induces growth arrest in PC3 prostate cancer cells.  
4.6.1 Growth-Inhibition in LNCaP and PC3 cells by D. denneanum  
Treatment of LNCaP and PC3 cells with purified D. denneanum generated a 
concentration-dependent ablation of cellular growth as shown in Figure 23. 
 
Figure 23. Purified Dendrobium denneanum thwarts growth of prostate cancer cells. (A) Assessment of PC3 cells 
treated with varying concentrations of compounds purified from Dendrobium d. (B) Assessment of PC3 cells treated 
with varying concentrations of compounds purified from Dendrobium d. 
Each of the compounds purified from D. denneanum significantly halted growth of 
both LNCaP and PC3 prostate cancer cells at micromolar concentrations. Evaluation of 




in Figure 24. Other compounds purified from D. nobile did not alter growth of LNCaP 
cells, significantly. 
 
Figure 24. Assessment of Purified Dendrobium nobile on LNCaP cell growth. LNCaP cells treated with peak-fractions 
purified D. nobile alters cell growth. 
Evaluation of compounds p54 and p56, from D. nobile also abolished cell growth 
of PC3 cells shown in Figure 25. Other compounds purified from D. nobile did not alter 







Figure 25. Assessment of Purified Dendrobium nobile on PC3 cell growth. PC3 cells treated with peak-fractions 






4.6.2 Growth-arrest of prostate cancer cells by D. denneanum  
To examine more precisely how this growth ablation was achieved, we analyzed 
cell cycle progression of PC3 cells treated with the crude compounds. Illustrated in 
Figure 26, D. denneanum significantly elicited an arrest of PC3 cells in the G1-phase of 
the cell cycle as shown in Figure 26. 
 
Figure 26. Dendrobium denneanum.arrests cell growth. Growth arrest of PC3 cells treated with D. denneanum. Cell 





Furthermore, there was not a significant change in the treated population of cells 
in sub-G1-phase as compared against control cells as shown in Figure 26. Together, this 
data suggests that crude D. denneanum arrests cell growth without induction of apoptosis. 
Given the results that D. denneanum halts cell growth by forcing cells to arrest at G1, we 
next wanted to investigate the potential for proliferating cells to respond to treatment as 
well. 
4.7 Suppression of proliferation by D. denneanum  
To assess the effect of compounds on prostate cancer cells, we treated PC3 cells 
with crude and purified D. denneanum. Cells were incubated with Bromodeoxyuridine 
(BrdU) and counter stained using anti-BrdU. Depicted in Figure 27,   crude D. denneanum 
abated proliferation in both PC3 cells. In a concentration-dependent manner, crude D. 
denneanum arrested proliferation of aggressive prostate cancer cells as compared to cells 
that did not receive compound treatments. Inhibition of proliferation is reported in Figure 
27B and 27C as compared to 27A. Cells positive for BrdU are quantitated in Figure 27F. 
Similarly, PC3 cells were incubated for 2 hours using BrdU and counterstained as 
mentioned previously. Compound 3 purified from D. denneanum also thwarted 
proliferation of PC3 prostate cancer cells, shown in Figure 27. In a concentration-
dependent manner, D. denneanum suppressed proliferation in prostate cancer cells depicted 
in Figure 27D and 27E, as compared to control cells in Figure 27A.  Cells positive for BrdU 





Figure 27. Inhibition of PC3 cell proliferation by D. denneanum. (A) Control cells treated with DMSO. (B) 
Cells treated with crude extract. (C) Cells treated with crude extract. (D) Cells treated with purified extract. 






4.8 Regulation of cellular targets by PRMT5-inhibition. 
Inhibition of PRMT5 methyltransferase activity results in differential expression 
at the genomic and proteomic levels as shown in Figure 28. Depicted in Figure 28A, 
PRMT5-inhibition generated a concentration dependent reduction in histone H2A protein 
levels. 
 
Figure 28. Inhibition of PRMT5 alters gene and protein levels. (A) Assessment of histone modification post-exposure 




Reduction in histone H2A protein levels was also achieved using other known 
PRMT5 inhibitors, EPZ0015666 and C9a, but not with compound 4 purified from D. 
denneanum as shown in Figure 28. 
 Inhibition of PRMT5 by crude and purified D. denneanum generated differential 
alterations in the expression of multiple genes of PC3 cells. The BTG family member 2 
anti-apoptosis gene, BTG2 was overexpressed following PRMT5 inhibition (Figure 28). 
The receptor tyrosine kinase family member, ErbB3 was suppressed upon inhibition of 
PRMT5 (Figure 28). The fibroblast growth factor receptor 3 FGFR3 was also suppressed 
following PRMT5 inhibition (Figure 28). The kinetochore associated gene, ZWINT was 
downregulated upon inhibition of PRMT5 (Figure 28). The differential gene expression 











 While studies have reported diverse groups of compounds in Dendrobium plants which 
possess various biological activities 219, there have been no reports of PRMT-inhibitory 
constituents in these plants.   In the present study, we provide evidence, for the first time, 
that two Dendrobium species contain multiple constituents that inhibited the activity of 
both type I and II protein arginine methyltransferases.  Three such constituents have been 
purified to homogeneity with molecular weights of 592.2766, 427.21, 535.15 Da.  The 
purified constituents inhibited growth of prostate cancer cells, which correlated well with 
their inhibitory activity on symmetric protein arginine dimethylation. 
5.1  Dendrobium Plants Contain PRMT-Inhibitory Compounds 
 By conventional extraction and chromatographic methods, we isolated 4 and 2 PRMT-
inhibitory constituents from D. nobile and D. denneanum, respectively.  These constituents 
inhibited the activity of both type I (PRMT1 and PRMT3) and type II (PRMT5) protein 
arginine methyltransferases with IC50 values from 0.2 to 32 g/ml.  Some constituents 
demonstrated the moderate (about 4-fold) selectivity for PRMT5 than PRMT 1 and 
PRMT3.  One constituent from D. nobile contained a compound with the molecular weight 




IC50 at 0.2 g/ml (0.3 M), which is comparable with PRMT5-specific inhibitors 
recently identified by screening chemical libraries.193-195, 220 These results suggested that 
Dendrobium plants contain multiple potent PRMT inhibitors.   The Dendrobium PRMT-
inhibitors also inhibited the protein arginine methylation in prostate cancer cells and 
affected expression of some PRMT5-target genes.  The future study would use a genome-
wide approach to determine genes whose expression is affected by Dendrobium 
inhibitors of PRMTs. 
5.2 Inhibition of PRMT5 Methyltransferase  
In a cell-free assay using purified recombinant proteins, we observed alterations 
in methylation patterns of known PRMT5 histone substrates. Consistent with published 
observations190, the arginine methylation at histone H2A was detected (Figure 28A, lane 
1), which was significantly inhibited by the crude extract (lanes 2 and 3) as well as the 
compound 3 peak-fraction (lane 4).  Two identified PRMT5 inhibitors (C9a and EPZ)190, 
221 were included in the assay as positive controls (Figure 28A, lanes 5 and 6).  Thus, 
PRMT-inhibitory compounds from D. denneanum inhibited the symmetrical arginine 
dimethylation of histones in cells. These results suggested that Dendrobium plants 
contain multiple potent PRMT inhibitors.  
 A set of genes regulated by PRMT5 and mediated its functions was identified. 222  
To investigate whether purified compounds affected expression of these genes, RT-PCR 
was performed with total RNAs isolated from PC3 cells treated with the crude extract 




expression of a PRMT5 down-regulated gene (BTG2) was up-regulated when PC3 cells 
were treated with the crude extract or the A set of genes regulated by PRMT5 and 
mediated its functions was identified 222.  To investigate whether purified compounds 
affected expression of these genes, RT-PCR was performed with total RNAs isolated 
from PC3 cells treated with the crude extract (100 µg/ml) or compound 3 peak-fraction 
(1.2 or 2.4 g/ml).   We found that expression of a PRMT5 down-regulated gene (BTG2) 
was up-regulated when PC3 cells were treated with the crude extract or compound 3 
peak-fraction (Figure 28B).  On the other hand, expression of PRMT5-upregulated genes 
(ErbB3, FGFR3, and ZWINT) was down-regulated by the crude extract or the purified 
compound 3 peak-fraction.  These results are consistent with the results obtained with 
PRMT5 silencing experiments. 222  Therefore, the isolated compound from D. denneanum 
inhibited PRMT5 activity and regulated its target gene expression in cells.  These data 
indicate that PRMT5-inhibitory compounds regulate PRMT5 functions in vivo.  A future 
study would use a genome-wide approach to determine genes whose expression is 
affected by PRMT inhibitors of Dendrobium.  
5.3 PRMT5-Mediated Growth Suppression 
Given the fact that PRMT5 plays critical roles in the growth of cancer cells21, 25, 
we tested whether the purified PRMT-inhibitory compounds could inhibit growth of 
prostate cancer PC3 and LNCaP cells.  The crude extract inhibited growth of both PC3 
and LNCaP cells in a dosage-dependent manner with IC50 values of 33 mg/mL and 85 




inhibited growth of PC3 and LNCaP cells in a dosage-dependent manner (Figure 23) and 
their IC50 values are in the ranges from 4.6 to 12.65 µg/mL.  The protein levels of 
PRMT5 and WDR77 were not affected by the treatment of PC3 cells with the crude 
extract, suggesting that cell growth inhibition induced by the crude extract is not through 
down-regulation of PRMT5 or WDR77 expression rather than inhibition of PRMT5 
activity.   
Silencing PRMT5 expression resulted in cell cycle arrest in the G1 phase.21  Both 
crude extract and the purified compound 3 peak-fraction induced G1 cell cycle arrest and 
decreased cell populations in the S phase (Figure 26), consistent with the observation that 
crude extract and the purified compound 3 inhibited PRMT5 activity.  It was observed 
that the purified constituent compound 3 also significantly decreased the cell population 
in the G2 phase.  The crude extract and purified compound did not induce apoptosis 
because they did not affect subG1 cell populations (Figure 26).   
 We previously showed that the enzymatic activity of PRMT5 is required for cellular 
proliferation.25  The BrdU incorporation assay was used to measure proliferative cells.  
Thirty-one percent of PC3 cells were BrdU-positive when cells were cultured in the 
presence of DMSO (Figure 27F).  In contrast, the treatment of PC3 cells with the crude 
extract (Figure 27 A, B and C) or the purified compound 3 peak-fraction (Figure 27 A, D 
and E) significantly decreased cell populations of BrdU-positive cells in a dosage-
dependent manner, suggesting that the crude extract and the purified compound inhibited 








We found in literature other studies providing evidence of extraction of 
phytochemical compounds from the orchid species Dendrobium d.215-216 A number of 
studies have evaluated the species of orchid reported here, as well as other species of 
orchid plants, for use against a number of maladies, including cancer.136, 223-227 We did 
not find published studies utilizing our methods of extraction conditions or inhibition of 
protein arginine methyltransferase activity.  
PRMT5 is frequently overexpressed or upregulated in multiple cancer types. 
Hyperactivity of PRMT5 correlates with cancer progression. PRMT5 localized to the 
cytoplasm in LNCaP cells promoted growth of prostate cancer cells. Knockdown of 
PRMT5 ablated cellular growth in A549 cells. Furthermore, mutation of PRMT5’s 
catalytic domain rendering the enzyme catalytically inactive thwarted growth of A549 
and LNCaP cells.21, 25, 228 Chemically targeting PRMT5 for inhibition of its 
methyltransferase activity generated reduced tumor volume and size in vivo.  Many 
studies have reported a number of compounds designed to inhibit PRMT5 
methyltransferase activity.21, 125, 132, 144, 190, 228-230 There is also a number of current studies 
seeking to discover new PRMT5 inhibitors. Scientific interest for the development of 




to the discovery of natural probes that target PRMT5 for inhibition of its 
methyltransferase activity.    
PRMTs have been shown to be upregulated in a number of different cancers and 
plays an essential role in growth of various cancer cells.132, 192  Consistent with these 
observations, PRMT5-inhibitors suppressed growth of lymphoma, AML, and MCL cells 
in tissue culture. 193-195  More recently, EPZ015666 demonstrated antitumor activity in 
multiple MCL xenograft models.195  Previous studies used RNA interference 
technologies revealed an essential role PRMT5 in growth of lung cancer cells and lung 
tumor xenografts.21  We have shown in this report that identified Dendrobium PRMT-
inhibitors inhibited growth of prostate cancer cells.  This inhibitory effect on cell growth 
is through the arrest of cells in G1 phase of the cell cycle, not through induction of 
apoptosis. These observations are consistent with the documented role of PRMT5 in the 
control of cellular proliferation.21, 231  These data imply that the observed inhibitory effect 
of Dendrobium isolates on growth of prostate cancer cells may be due to the suppression 
of the PRMT5 activity. In the future, we plan to evaluate the observed effects in a murine 
model. In addition to resolving the structure of compound 3 from D. denneanum, we plan 
to evaluate the enzyme kinetics for association, stability, and mechanism of inhibition. 
We intend to determine the effects of D. denneanum, if any, on protein lysine 
methyltransferases and the modification of histone protein tails. Lastly, we plan to 
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